{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:37:24Z","timestamp":1793504244349,"version":"4.5.0"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020921","name":"Indo Soviet Friendship College of Pharmacy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["45\/11\/2019-BIO\/BMS"],"award-info":[{"award-number":["45\/11\/2019-BIO\/BMS"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.bioorg.2023.107077","type":"journal-article","created":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T11:06:25Z","timestamp":1703934385000},"page":"107077","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["A comprehensive review of small molecules targeting PI3K pathway: Exploring the structural development for the treatment of breast cancer"],"prefix":"10.1016","volume":"143","author":[{"given":"Rahul","family":"Dubey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anushka","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.D.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4990-7757","authenticated-orcid":false,"given":"Vivek","family":"Asati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2023.107077_b0005","first-page":"13","article-title":"Global cancer incidences, causes and future predictions for subcontinent region","volume":"6","author":"Kamil","year":"2015","journal-title":"Sys. Rev. Pharm."},{"key":"10.1016\/j.bioorg.2023.107077_b0010","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","article-title":"Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018","author":"Ferlay","year":"2018","journal-title":"Eur. J. Cancer."},{"issue":"4","key":"10.1016\/j.bioorg.2023.107077_b0015","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.fertnstert.2008.08.067","article-title":"Female reproductive disorders: the roles of endocrine-disrupting compounds and developmental timing","volume":"90","author":"Crain","year":"2008","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.bioorg.2023.107077_b0020","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10549-008-0099-x","article-title":"Columnar cell lesions, mammographic density and breast cancer risk","volume":"115","author":"Gulisa","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.bioorg.2023.107077_b0025","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(19)31709-X","article-title":"Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence","volume":"394","author":"Beral","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2023.107077_b0030","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jcpo.2015.03.002","article-title":"Why have breast cancer mortality rates declined?","volume":"5","author":"Narod","year":"2015","journal-title":"J. Cancer Policy."},{"key":"10.1016\/j.bioorg.2023.107077_b0035","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.breast.2012.08.005","article-title":"Association between common risk factors and molecular subtypes in breast cancer patients","volume":"22","author":"Turkoz","year":"2013","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.bioorg.2023.107077_b0040","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.breast.2013.11.007","article-title":"High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer","volume":"23","author":"Criscitiello","year":"2014","journal-title":"Breast"},{"key":"10.1016\/j.bioorg.2023.107077_b0045","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/modpathol.3800830","article-title":"Predominance of the basal type and HER-2\/neu type in brain metastasis from breast cancer","volume":"20","author":"Gaedcke","year":"2007","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bioorg.2023.107077_b0050","first-page":"215","article-title":"Expression of ER, PR, and Her-2\/neu in endometrial cancer: a clinicopathological study","volume":"11","author":"Srijaipracharoen","year":"2010","journal-title":"Asian Pac J Cancer Prev."},{"key":"10.1016\/j.bioorg.2023.107077_b0055","doi-asserted-by":"crossref","first-page":"vi7-vi12","DOI":"10.1093\/annonc\/mds187","article-title":"Triple-negative breast cancer: epidemiological considerations and recommendations","volume":"23","author":"Boyle","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2023.107077_b0060","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/cam4.998","article-title":"Opportunities for improving triple-negative breast cancer outcomes: results of a population-based study","volume":"6","author":"Rapiti","year":"2017","journal-title":"Cancer Med."},{"key":"10.1016\/j.bioorg.2023.107077_b0065","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10555-019-09811-7","article-title":"Cell surface\u2013anchored serine proteases in cancer progression and metastasis","volume":"38","author":"Martin","year":"2019","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.bioorg.2023.107077_b0070","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/j.ajpath.2018.05.020","article-title":"Assessment of functional phosphatidylinositol 3-kinase pathway activity in cancer tissue using forkhead box-O target gene expression in a knowledge-based computational model","volume":"188","author":"Ooijen","year":"2018","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bioorg.2023.107077_b0075","doi-asserted-by":"crossref","unstructured":"Y. Wang, A. Minden A, Current molecular combination therapies used for the treatment of breast cancer, Int.J.Mol.Sci., 23 (2022) 11046, https:\/\/doi.org\/ 10.3390\/ijms231911046.","DOI":"10.3390\/ijms231911046"},{"key":"10.1016\/j.bioorg.2023.107077_b0080","first-page":"59","article-title":"Predicting and overcoming chemotherapeutic resistance in breast cancer translational research in breast cancer: biomarker diagnosis","volume":"1026","author":"Chun","year":"2017","journal-title":"Targeted Therapies and Approaches to Precision Medicine."},{"key":"10.1016\/j.bioorg.2023.107077_b0085","doi-asserted-by":"crossref","first-page":"957","DOI":"10.3390\/cells8090957","article-title":"Mechanisms of chemotherapy resistance in triple-negative breast cancer\u2014how we can rise to the challenge","volume":"8","author":"Nedeljkovic","year":"2019","journal-title":"Cells."},{"key":"10.1016\/j.bioorg.2023.107077_b0090","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.semcancer.2019.05.012","article-title":"Role of the PI3K\/AKT\/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance","volume":"59","author":"Ediriweera","year":"2019","journal-title":"Semin. Cancer Biol., Elsevier."},{"key":"10.1016\/j.bioorg.2023.107077_b0095","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3390\/cancers12020491","article-title":"Molecular signaling pathways and therapeutic targets in hepatocellular carcinoma","volume":"12","author":"Dimri","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2023.107077_b0100","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/onc.2012.130","article-title":"The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies","volume":"32","author":"Luo","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2023.107077_b0105","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.semcancer.2021.06.019","article-title":"Attacking the PI3K\/Akt\/mTOR signaling pathway for targeted therapeutic treatment in human cancer","volume":"85","author":"Yu","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bioorg.2023.107077_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101364","article-title":"The PI3K\/Akt\/mTOR pathway in lung cancer; oncogenic alterations, therapeutic opportunities, challenges, and a glance at the application of nanoparticles","volume":"18","author":"Sanaei","year":"2022","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.bioorg.2023.107077_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-021-07826-4","article-title":"Diverse mechanisms activate the PI3-kinase\/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK","volume":"21","author":"Tran","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bioorg.2023.107077_b0120","doi-asserted-by":"crossref","first-page":"738","DOI":"10.2174\/156802609789044434","article-title":"Small molecule inhibitors of phosphoinositide 3-kinase (PI3K) \u03b4 and \u03b3","volume":"9","author":"Ameriks","year":"2009","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.107077_b0125","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1471-4892(03)00078-X","article-title":"Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents","volume":"3","author":"Ward","year":"2003","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.bioorg.2023.107077_b0130","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1358\/dof.2015.040.04.2302828","article-title":"Phosphatidylinositol 3-kinase alpha (PI3Kalpha) inhibitor Oncolytic","volume":"40","author":"Heymann","year":"2015","journal-title":"Drugs Future"},{"key":"10.1016\/j.bioorg.2023.107077_b0135","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ygcen.2017.04.002","article-title":"Characterization and mechanism of phosphoinositide 3-kinases (PI3Ks) members in insulin-induced changes of protein metabolism in yellow catfish Pelteobagrus fulvidraco","volume":"247","author":"Zhuo","year":"2017","journal-title":"Gen. Comp. Endocrinol."},{"key":"10.1016\/j.bioorg.2023.107077_b0140","first-page":"17","article-title":"Protease-Activated Receptors (PARs);An illustrated review","volume":"5","author":"Han","year":"2021","journal-title":"Encyclopedia of Molecular Pharmacology: Research and Practice in Thrombosis and Haemostasis."},{"key":"10.1016\/j.bioorg.2023.107077_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-017-0670-3","article-title":"Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development","volume":"16","author":"Zhao","year":"2017","journal-title":"Mol. Cancer."},{"key":"10.1016\/j.bioorg.2023.107077_b0150","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/annonc\/mdz381","article-title":"Efficacy of PI3K inhibitors in advanced breast cancer","volume":"30","author":"Verret","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2023.107077_b0155","doi-asserted-by":"crossref","unstructured":"M. Zhang, H. Jang, R. Nussinov, Structural features that distinguish inactive and active PI3K lipid kinases, J.Mol.Biol., 432 (2020) 5849-59, http:\/\/dx.doi.org\/ 10.1016\/j.jmb.2020.09.002.","DOI":"10.1016\/j.jmb.2020.09.002"},{"key":"10.1016\/j.bioorg.2023.107077_b0160","doi-asserted-by":"crossref","unstructured":"B. Bilanges, Y. Posor, B. Vanhaesebroeck, PI3K isoforms in cell signalling and vesicle trafficking, Nat. Rev. Mol. Cell Biol. 20 (2019) 515-34, http:\/\/dx.doi.org\/ 10.1038\/s41580-019-0129-z.","DOI":"10.1038\/s41580-019-0129-z"},{"key":"10.1016\/j.bioorg.2023.107077_b0165","doi-asserted-by":"crossref","unstructured":"D. Miricescu, A. Totan, I-I. Stanescu-Spinu, S.C. Badoiu, C. Stefani, M. Greabu, PI3K\/AKT\/mTOR signaling pathway in breast cancer: from molecular landscape to clinical aspects, Int.J.Mol.Sci.22 (2020) 173. http:\/\/dx.doi.org\/ 10.3390\/ijms22010173.","DOI":"10.3390\/ijms22010173"},{"key":"10.1016\/j.bioorg.2023.107077_b0170","doi-asserted-by":"crossref","unstructured":"N.S. Clayton, M. Fox, J.J.V. Garcia, C.M. Schroeder, T.D. Littlewood, J.L. Wilde, J. Corry, K. Krishnan, Q. Zhang, M.J.O. Wakelam, M.J.B. Brown, C. Crafter, H.R. Mott, D. Owen, Assembly of novel, nuclear dimers of the PI3-Kinase regulatory subunits underpins the pro-proliferative activity of the Cdc42-activated tyrosine kinase, ACK, BioRxiv. (2019):791277. https:\/\/doi.org\/10.1101\/791277.","DOI":"10.1101\/791277"},{"key":"10.1016\/j.bioorg.2023.107077_b0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-018-0801-5","article-title":"Advances in studies of tyrosine kinase inhibitors and their acquired resistance","volume":"17","author":"Jiao","year":"2018","journal-title":"Mol. Cancer."},{"key":"10.1016\/j.bioorg.2023.107077_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114039","article-title":"Molecular design of dual inhibitors of PI3K and potential molecular target of cancer for its treatment: A review","volume":"228","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.107077_b0185","doi-asserted-by":"crossref","first-page":"86","DOI":"10.37349\/ent.2021.00008","article-title":"Striking a balance: PIP2 and PIP3 signaling in neuronal health and disease","volume":"1","author":"Tariq","year":"2021","journal-title":"Exploration of Neuroprotective Therapy."},{"key":"10.1016\/j.bioorg.2023.107077_b0190","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00232-016-9909-y","article-title":"Features of the phosphatidylinositol cycle and its role in signal transduction","volume":"250","author":"Epand","year":"2017","journal-title":"J. Membr. Biol."},{"key":"10.1016\/j.bioorg.2023.107077_b0195","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s13402-022-00715-3","article-title":"Molecular mechanisms underlying the action of carcinogens in gastric cancer with a glimpse into targeted therapy","volume":"45","author":"Patrad","year":"2022","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.bioorg.2023.107077_b0200","first-page":"4529","article-title":"Research progress on the PI3K\/AKT signaling pathway in gynecological cancer","volume":"19","author":"Shi","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.bioorg.2023.107077_b0205","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cytogfr.2019.03.001","article-title":"Role of the PI3K\/AKT (mTOR and GSK3\u03b2) signalling pathway and photobiomodulation in diabetic wound healing","volume":"50","author":"Jere","year":"2019","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.bioorg.2023.107077_b0210","doi-asserted-by":"crossref","first-page":"16033","DOI":"10.1021\/acs.jmedchem.2c01070","article-title":"Targeting the PI3K\/AKT\/mTOR signaling pathway in the treatment of human diseases: Current status, trends, and solutions","volume":"65","author":"Huang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.107077_b0215","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2217\/fon-2020-0464","article-title":"Alpelisib in the treatment of metastatic HR+ breast cancer with PIK3CA mutations","volume":"17","author":"Mavratzas","year":"2021","journal-title":"Future Oncol."},{"issue":"7","key":"10.1016\/j.bioorg.2023.107077_b0220","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1158\/1078-0432.CCR-20-3652","article-title":"FDA approval summary: alpelisib plus fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer","volume":"27","author":"Narayan","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2023.107077_b0225","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40487-017-0046-2","article-title":"A review of fulvestrant in breast cancer","volume":"5","author":"Nathan","year":"2017","journal-title":"Oncology and Therapy."},{"key":"10.1016\/j.bioorg.2023.107077_b0230","first-page":"004","article-title":"Combined targeting of PI3K and MEK effector pathways via CED for DIPG therapy","volume":"1","author":"Chang","year":"2019","journal-title":"Neuro-Oncol. Adv."},{"issue":"4","key":"10.1016\/j.bioorg.2023.107077_b0235","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.3390\/ijms24043643","article-title":"Targeting breast cancer: an overlook on current strategies","volume":"24","author":"Iacopetta","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bioorg.2023.107077_b0240","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11523-017-0482-9","article-title":"A phase Ib study of the dual PI3K\/mTOR inhibitor dactolisib (BEZ235) combined with everolimus in patients with advanced solid malignancies","volume":"12","author":"Wise-Draper","year":"2017","journal-title":"Target. Oncol."},{"key":"10.1016\/j.bioorg.2023.107077_b0245","first-page":"47","article-title":"Targeting the PI3K\/AKT\/mTOR and RAF\/MEK\/ERK pathways for cancer therapy","volume":"3","author":"Li","year":"2022","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.bioorg.2023.107077_b0250","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s43018-021-00218-4","article-title":"The present and future of PI3K inhibitors for cancer therapy","volume":"2","author":"Castel","year":"2021","journal-title":"Nature Cancer"},{"key":"10.1016\/j.bioorg.2023.107077_b0255","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.2174\/1568026620666200106141717","article-title":"Isoform-selective PI3K inhibitors for various diseases","volume":"20","author":"Bheemanaboina","year":"2020","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.107077_b0260","article-title":"Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed\/refractory T-cell lymphoma: results from a phase I\/II open-label multicenter study","volume":"108","author":"Iyer","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.bioorg.2023.107077_b0265","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.clml.2019.10.013","article-title":"A first-in-human study of Tenalisib (RP6530), a dual PI3K \u03b4\/\u03b3 inhibitor, in patients with relapsed\/refractory hematologic malignancies: results from the european study","volume":"20","author":"Stella","year":"2020","journal-title":"Clin. Lymphoma. Myeloma. Leuk."},{"key":"10.1016\/j.bioorg.2023.107077_b0270","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ygyno.2019.12.002","volume":"156","author":"Arend","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2023.107077_b0275","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1158\/1078-0432.CCR-14-0947","article-title":"First-in-human phase I study of pictilisib (GDC-0941), a potent pan\u2013class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors","volume":"21","author":"Sarker","year":"2015","journal-title":"Clin. Cancer. Res."},{"key":"10.1016\/j.bioorg.2023.107077_b0280","first-page":"2018\/01\/17","article-title":"Combination therapy using PDK1 and PI3K inhibitors","volume":"11696924 B2","author":"Pau","year":"2023","journal-title":"US Patent US"},{"key":"10.1016\/j.bioorg.2023.107077_b0285","first-page":"2017\/02\/17","article-title":"byl719 (alpelisib) for use in the treatment of pik3ca-related overgrowth spectrum (pros-cloves syndrome)","volume":"2020\/0215044 A1","author":"Guillaume","year":"2020","journal-title":"US Patent US"},{"key":"10.1016\/j.bioorg.2023.107077_b0290","first-page":"2015\/06\/17","article-title":"Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor and\/or a JAK-2 Inhibitor","volume":"2017\/0136014 A1","author":"Ahmed","year":"2017","journal-title":"US Patent US"},{"key":"10.1016\/j.bioorg.2023.107077_b0295","unstructured":"R.D Brian, V.D. Marcian, W. Christopher (2016) dual mek\/pi3k inhibitors and therapeutic methods using the same. US patent US 2016\/0002212 A1.2014\/03\/12. https:\/\/link.lens.org\/4EUegHHtBsk."},{"key":"10.1016\/j.bioorg.2023.107077_b0300","first-page":"2013\/11\/07","article-title":"Pharmaceutical compositions containing a PDE4 inhibitor and a PI3K delta or dual PI3 delta-gamma kinase inhibitor","volume":"9737521 B2","author":"Vakkalanka","year":"2017","journal-title":"US Patent US"},{"key":"10.1016\/j.bioorg.2023.107077_b0305","unstructured":"N. Kijosi , S. Kazujuki , S. Masaki , T. Juiti , S. Masanori , O. Takasi (2013) Morpholinopurine derivatives, having pi3k and\/or mtor inhibiting activity. RU patent RU 2490269 C2. 2009\/10\/13. https:\/\/link.lens.org\/q9kfDiie2Fk."},{"key":"10.1016\/j.bioorg.2023.107077_b0310","unstructured":"B. William , B.L Canne , B.S. David , K. Patrick , M.B Morrison, M.K Charles , N.M John, T. Zerom , W. Yong , X. Wei (2011) Phosphatidylinositol 3-kinase inhibitors and methods of their use. US patent US 7989622 B2. 2006\/10\/09. https:\/\/link.lens.org\/IMYQyFD8uyh."},{"key":"10.1016\/j.bioorg.2023.107077_b0315","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejmech.2017.07.033","article-title":"Recent advances (2015\u20132016) in anticancer hybrids","volume":"142","author":"Kerru","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"79","key":"10.1016\/j.bioorg.2023.107077_b0320","first-page":"1","article-title":"Pyrrolidine in drug discovery: a versatile scaffold for novel biologically active compounds","volume":"3","author":"Petri","year":"2021","journal-title":"Top Curr Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2023.107077_b0325","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.3390\/molecules28114278","article-title":"Antitumor activity of s-triazine derivatives: a systematic review","volume":"28","author":"Dai","year":"2023","journal-title":"Mol."},{"key":"10.1016\/j.bioorg.2023.107077_b0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.117133","article-title":"Design, synthesis and antitumor activity of novel thiophene-triazine derivatives bearing arylurea unit as potent PI3K\/mTOR inhibitorss","volume":"78","author":"Xu","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.107077_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2022.134633","article-title":"Curcumin based pyrazole-thiazole hybrids as antiproliferative agents: Synthesis, pharmacokinetic, photophysical properties, and docking studies","volume":"1275","author":"Palabindela","year":"2023","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2023.107077_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105257","article-title":"Novel 1, 3, 4-thiadiazole\/oxadiazole-linked honokiol derivatives suppress cancer via inducing PI3K\/Akt\/mTOR-dependent autophagy","volume":"115","author":"Xu","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2023.107077_b0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104872","article-title":"Design, synthesis and biological evaluation of anilide (dicarboxylic acid) shikonin esters as antitumor agents through targeting PI3K\/Akt\/mTOR signaling pathway","volume":"111","author":"Ma","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2023.107077_b0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116107","article-title":"Synthesis and evaluation of novel thiosemicarbazone and semicarbazone analogs with both anti-proliferative and anti-metastatic activities against triple negative breast cancer","volume":"37","author":"Bai","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.107077_b0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112309","article-title":"Design, synthesis and biological activity of novel 2, 3, 4, 5-tetra-substituted thiophene derivatives as PI3K\u03b1 inhibitors with potent antitumor activity","volume":"197","author":"Liao","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.107077_b0360","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.3390\/molecules23071553","article-title":"Design, Synthesis and biological evaluation of novel phenylsulfonylurea derivatives as PI3K\/mTOR dual inhibitors","volume":"23","author":"Zhao","year":"2018","journal-title":"Mol."},{"key":"10.1016\/j.bioorg.2023.107077_b0365","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bioorg.2018.03.006","article-title":"Curcumin analogue 1, 5-bis (4-hydroxy-3-((4-methylpiperazin-1-yl) methyl) phenyl) penta-1, 4-dien-3-one mediates growth arrest and apoptosis by targeting the PI3K\/AKT\/mTOR and PKC-theta signaling pathways in human breast carcinoma cells","volume":"78","author":"Badr","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2023.107077_b0370","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejmech.2017.08.067","article-title":"Design, synthesis and structure-activity relationship studies of a focused library of pyrimidine moiety with anti-proliferative and anti-metastasis activities in triple negative breast cancer","volume":"140","author":"Yao","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.107077_b0375","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ejmech.2018.09.002","article-title":"Synthesis, biological evaluation and structure-activity relationship of a novel class of PI3K\u03b1 H1047R mutant inhibitors","volume":"158","author":"Zhang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2023.107077_b0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.arabjc.2021.103614","article-title":"Synthesis, in-silico, and in-vitro study of novel chloro methylquinazolinones as PI3K-\u03b4 inhibitors, cytotoxic agents","volume":"15","author":"Elfeky","year":"2022","journal-title":"Arab. J. Chem."},{"key":"10.1016\/j.bioorg.2023.107077_b0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115957","article-title":"Synthesis, antitumor activity and structure-activity studies of novel pyridoxine-based bioisosteric analogs of estradiol","volume":"30","author":"Pugachev","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.107077_b0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104569","article-title":"Design, synthesis and in silico insights of new 7, 8-disubstituted-1, 3-dimethyl-1H-purine-2, 6 (3H, 7H)-dione derivatives with potent anticancer and multi-kinase inhibitory activities","volume":"107","author":"Mohamed","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2023.107077_b0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115976","article-title":"Synthesis, anticancer and antimicrobial evaluation of new benzofuran based derivatives: PI3K inhibition, quorum sensing and molecular modeling study","volume":"31","author":"El-Khouly","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.107077_b0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103845","article-title":"Synthesis and anticancer evaluation of novel 1H-benzo [d] imidazole derivatives of dehydroabietic acid as PI3K\u03b1 inhibitors","volume":"100","author":"Yang","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2023.107077_b0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103569","article-title":"Synthesis of a novel series of (Z)-3, 5-disubstituted thiazolidine-2, 4-diones as promising anti-breast cancer agents","volume":"96","author":"El-Kashef","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2023.107077_b0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112637","article-title":"Design, synthesis and bioevaluation of novel substituted triazines as potential dual PI3K\/mTOR inhibitors","volume":"204","author":"Wu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.107077_b0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103086","article-title":"Design, synthesis and biological evaluation of novel thieno [3, 2-d] pyrimidine and quinazoline derivatives as potent antitumor agents","volume":"90","author":"Hu","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2023.107077_b0420","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1002\/jhet.3202","article-title":"Synthesis of Substituted Quinolinyl Ether-based Inhibitors of PI3K as Potential Anticancer Agents","volume":"55","author":"Aggile","year":"2018","journal-title":"J. Heterocycl. Chem."},{"key":"10.1016\/j.bioorg.2023.107077_b0425","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.bmc.2017.12.025","article-title":"Discovery of new thienopyrimidine derivatives as potent and orally efficacious phosphoinositide 3-kinase inhibitors","volume":"26","author":"Lin","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.107077_b0430","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejmech.2017.02.015","article-title":"Design, synthesis, and biological evaluation of imidazo [1, 2-b] pyridazine derivatives as mTOR inhibitors","volume":"129","author":"Mao","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.107077_b0435","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejmech.2019.02.003","article-title":"Pyranocarbazole derivatives as potent anti-cancer agents triggering tubulin polymerization stabilization induced activation of caspase-dependent apoptosis and downregulation of Akt\/mTOR in breast cancer cells","volume":"167","author":"Patel","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.107077_b0440","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ejmech.2017.11.097","article-title":"Design and synthesis of novel quinacrine-[1, 3]-thiazinan-4-one hybrids for their anti-breast cancer activity","volume":"143","author":"Solomon","year":"2018","journal-title":"Eur. J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206823007381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206823007381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T11:56:49Z","timestamp":1777463809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206823007381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":88,"alternative-id":["S0045206823007381"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2023.107077","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comprehensive review of small molecules targeting PI3K pathway: Exploring the structural development for the treatment of breast cancer","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2023.107077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107077"}}